Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 13/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18429019 | 0.83 | GPR119 (0.47) | HPGDGPR119RECQLEPHX1 | |
| SCHEMBL393481 | 0.83 | HPGD (0.46) | HPGDGPR119RECQLEPHX1KDM4E | |
| SCHEMBL1101109 | 0.81 | GPR119 (0.46) | HPGDGPR119RECQLEPHX1MEN1 | |
| SCHEMBL31662685 | 0.79 | GPR119 (0.42) | HPGDGPR119RECQLEPHX1ALDH1A1 | |
| SCHEMBL1088765 | 0.79 | KDM4E (0.42) | HPGDGPR119RECQLEPHX1KDM4E | |
| SCHEMBL24680916 | 0.78 | USP30 (0.48) | HPGDGPR119RECQLEPHX1ALDH1A1 | |
| SCHEMBL24680917 | 0.78 | USP30 (0.48) | HPGDGPR119RECQLEPHX1ALDH1A1 | |
| SCHEMBL31208730 | 0.78 | USP30 (0.48) | HPGDGPR119RECQLEPHX1ALDH1A1 | |
| SCHEMBL24379206 | 0.78 | HPGD (0.47) | HPGDGPR119RECQLEPHX1NPC1 | |
| SCHEMBL16376310 | 0.78 | HPGD (0.51) | HPGDGPR119RECQLEPHX1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1812445-B1 | PHARMACEUTICAL COMPOUNDS | PIRAMED LTD (GB) | 2015-12-30 | — | — | EP | disclosed |
| US-8946217-B2 | Pharmaceutical compounds | F. HOFFMANN-LA ROCHE AG (CH) | 2015-02-03 | — | — | US | disclosed |
| US-20140294946-A1 | PHARMACEUTICAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-10-02 | — | — | US | disclosed |
| US-20130317017-A1 | PHARMACEUTICAL COMPOUNDS | F. HOFFMAN-LA ROCHE AG (CH) | 2013-11-28 | — | — | US | disclosed |
| US-20120258966-A1 | PHARMACEUTICAL COMPOUNDS | F. HOFFMAN-LA ROCHE AG (CH) | 2012-10-11 | — | — | US | disclosed |
| US-8153629-B2 | Pharmaceutical compounds | F. HOFFMANN-LA ROCHE AG (CH) | 2012-04-10 | — | — | US | disclosed |
| US-20100234370-A1 | PHARMACEUTICAL COMPOUNDS | PIRAMED LIMITED (GB) | 2010-09-16 | — | — | US | disclosed |
| US-7750002-B2 | Pharmaceutical compounds | PIRAMED LIMITED (GB) | 2010-07-06 | — | — | US | disclosed |
| US-20080207611-A1 | Pharmaceutical compounds | PLRAMED LIMITED (GB) | 2008-08-28 | — | — | US | disclosed |
| EP-1812445-A1 | PHARMACEUTICAL COMPOUNDS | Piramed Limited (GB) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006046031-A1 | PHARMACEUTICAL COMPOUNDS | PIRAMED LIMITED (GB) | 2006-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140294946-A1 | PHARMACEUTICAL COMPOUNDS | PIK3CA, JAK2, PIK3R1 | HPGD 3646/4885GPR119 37/4885RECQL 311/4885 |
| US-20100234370-A1 | PHARMACEUTICAL COMPOUNDS | PIK3CA, JAK2, PIK3R1 | HPGD 3646/4885GPR119 37/4885RECQL 311/4885 |
| US-20080207611-A1 | Pharmaceutical compounds | PIK3CA, JAK2, PIK3R1 | HPGD 3664/4885GPR119 39/4885RECQL 316/4885 |
| US-20120258966-A1 | PHARMACEUTICAL COMPOUNDS | PIK3CA, JAK2, PIK3R1 | HPGD 3646/4885GPR119 37/4885RECQL 311/4885 |
| US-20130317017-A1 | PHARMACEUTICAL COMPOUNDS | PIK3CA, JAK2, PIK3R1 | HPGD 3646/4885GPR119 37/4885RECQL 311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.